Long-Term Outcomes with Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency

Presented at ACAAI 2023

Authors:
Jeffrey W. Langford, MD, AE-C
Richard F. Herrscher, MD, FACAAI
Precious A. Anyanwu, PharmD, PhD
Lucinda J. Van Anglen, PharmD